Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $24
Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:FMS) with a Hold and lowers the price target from $25 to $24.
Stocks · News reference
Fresenius Medical Care Refines China Strategy With Targeted Product Focus
Fresenius Medical Care updates China strategy, and incurs a 110 million euro charge while focusing on advanced dialysis tech.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Fresenius Medical Care shares are trading lower after the company announced that Shervin Korangy will replace Helen Giza as the company's CEO on October 12.
Fresenius Medical Care Appoints Shervin J. Korangy As CEO Effective October 12; Shervin J. Korangy To Succeed Helen Giza
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced that Shervin J. Korangy (51) will become Chief Executive Officer (CEO) and
Fresenius Medical Care Shares Halted, News Pending